Pharmacology, Biochemistry and Behavior 1994: Vol 49 Index

10 Pages·1994·2.9 MB·English

PHARMACOLOGY
BIOCHEMISTRY
AND
BEHAVIOR
VOLUME 49, 1994
SUBJECT AND AUTHOR INDEX
©
PERGAMON
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
US Editor-in-Chief
MATTHEW J. WAYNER
Division of Life Sciences, The University of Texas at San Antonio, San Antonio, TX 78249-0662
European Editor-in-Chief
SANDRA E. FILE
Psychopharmacology Research Unit, UMDS Division of Pharmacology, Guy’s Hospital
P.O. Box 3448, London SE1 9QH, UK
Editorial Advisory Board
LIISA AHTEE, Helsinki, Finland CONAN KORNETSKY, Boston, MA
LEMBIT ALLIKMETS, Tartu, Estonia J. DAVID LEANDER, Indianapolis, IN
ROBERT L. BALSTER, Richmond, VA EMINY H. Y. LEE, Taipei, Taiwan
GIOVANNI BIGGIO, Cagliari, Italy ALLEN S. LEVINE, Minneapolis, MN
MIKE BRILEY, Castres, France WILLIAM J. McBRIDE, Indianapolis, IN
ALLAN C. COLLINS, Boulder, CO DONALD E. McMILLAN, Little Rock, AR
DONALD V. COSCINA, Toronto, Ontario, Canada JACK H. MENDELSON, Belmont, MA
JACQUELINE N. CRAWLEY, Bethesda, MD FATHY S. MESSIHA, Grand Forks, ND
ANNETTE DOMENEY, Geneva, Switzerland ROBERT D. MYERS, Greenville, NC
ADRIAN J. DUNN, Shreveport, LA JUDITH A. PRATT, Glasgow, UK
BURR EICHELMAN, Philadelphia, PA JAQUELINE SAGEN, Chicago, IL
WILLIAM J. FREED, Washington, DC ROSARIO SAMANIN, Milan, Italy
MANUEL FREIRE-GARABAL, Santiago De Compostela, Spain HERMAN H. SAMSON, Winston-Salem, NC
RICHARD A. GLENNON, Richmond, VA PAUL R. SANBERG, Tampa, FL
F. G. GRAEFF, Sao Paulo, Brazil PHIL J. SKOLNICK, Bethesda, MD
M. R. C. GREENWOOD, Davis, CA LINDA P. SPEAR, Binghamton, NY
ROLAND R. GRIFFITHS, Baltimore, MD CLARE STANFORD, London, UK
STEPHEN G. HOLTZMAN, Atlanta, GA MARIE-HELENE THIEBOT, Paris, France
AKIRA HORITA, Seattle, WA DEREK VAN DER KOOY, Toronto, Ontario, Canada
CHRIS E. JOHANSON, Baltimore, MD JEANNE M. WEHNER, Boulder, CO
HAROLD KALANT, Toronto, Ontario, Canada BRUNO E. WILL, Strasbourg, France
G. JEAN KANT, Washington, DC J. C. WINTER, Buffalo, NY
KATHLEEN M. KANTAK, Boston, MA ALICE M. YOUNG, Detroit, MI
GEORGE F. KOOB, La Jolla, CA IAN S. ZAGON, Hershey, PA
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
US Editorial Office:
Matthew J. Wayner
Division of Life Sciences, The University of Texas at San Antonio, 6900 North Loop 1604 West
San Antonio, TX 78249-0662
Fax: [phone]
European Editorial Office:
Sandra E. File
Psychopharmacology Research Unit, UMDS Division of Pharmacology, Guy’s Hospital
P.O. Box 3448, London SE1 9QH, UK
Fax: [phone]; E-mail: S.F [email protected]
Production Editor:
Alayne A. Bakken
E-mail: A.,[email protected]
Publishing, Subscription, and Advertising Offices:
Elsevier Science Inc., 660 White Plains Road, Tarrytown, NY 10591-5153, USA, E-mail Address:
[email protected]; and Elsevier Science Ltd, The Boulevard, Langford Lane, Kidlington,
Oxford OX5 1GB, England
Published Monthly
Annual Institutional Subscription Rates (1995): North, Central and South America, US$1580.00, Rest of World
£1060.00. Associated Personal Subscription Rates are available on request for those whose institutions are library
subscribers. Sterling prices exclude VAT. Non-VAT registered customers in the European Community will be
charged the appropriate VAT in addition to the price listed. Prices include postage and insurance and are subject to
change without notice.
Pharmacology Biochemistry and Behavior is an official journal of the International Behavioral Neuroscience
Society. For information about the society, please contact: Marianne Van Wagner, IBNS Central Office, Division
of Life Sciences, The University of Texas at San Antonio, 6900 North Loop 1604 West, San Antonio, TX 78249-
0662, USA. E-mail: [email protected]; Fax: (210) 691-4510. Members of the International
Behavioral Neuroscience Society may order personal subscriptions at a concessional rate; details of this rate are
available upon request.
Pharmacology Biochemistry and Behavior, Vol. 49, No. 4, pp. I-IX, 1994
Copyright © 1994 Elsevier Science Ltd
©) Pergamon
Printed in the USA. All rights reserved
0091-3057/94 $6.00 + .00
SUBJECT INDEX
Abuse liability, 643 Anticholinesterase, 363 CS57BL/6, 1109
Acetylcholine, 769, 807, 1067, 1075 Anticipatory vomiting, 385 Ca** signal, 669
Acoustic startle, 877, 935 Anticonvulsant, 1113 Calcium, 1093
Acquisition, 935 Anticonvulsant test, 47 Calcium transients, 405
Acrylamide, 443 Antidepressants, 263, 281 Calories, 629
Active avoidance, 33 Antiinflammatory, 335 cAMP, 1093
Activity feedback, 975 Antinociception, 649, 657, 675, 929, Cannabinoids, 929, 1093
Adaptation, 247 1093 Capsaicin-sensitive nerves, 253
Adenosine, 271 Anxiety, 327, 359, 393, 471, 549, 755, Carbachol, 835
Adenosine A, receptors, 271 801, 911 Cardiac arrest, 129
Adenosine A, receptors, 271 Anxiogenic drugs, 171 Cat odor, 219
Adrenergic, 295 Anxiolytic-like effect, 101 Catalepsy, 277
Adrenocortical stress response, 961 Anxiolytics, 171, 281, 741 Catecholamines, 33, 599
AF64A (ethyl choline mustard Apomorphine, 819 CCK-B agonists, 133
aziridinium), 33 Appetite, 187 CCK-B antagonists, 433
Affective-motivational, 827 Arcuate nucleus, 579 CCK-B receptors, 133
Age, 371, 497 Area postrema, 489 Central benzodiazepine binding, 47
Aged rats, 1075 Arterial blood pressure, 489 Central benzodiazepine receptor heteroge-
Aggression, 313, 483 Associative tolerance, 1029 neity, 47
Aggressive behavior, 13 Atipamezole, 523 Central locomotor activity (antiagorapho-
Aging monkeys, 235 Atropine, 1, 115 bic Inhibition), 711
Aging, 213, 683 Attention, 683 Central injection, 463
Agonists, 295 Autoradiography, 7 Cerebellar grafts, 443
AHR 11797, 47 Autoshaping, 1083 Cerebellum, 639, 777
a,-Adrenergic receptors, 897 Avoidance behavior, 1075 Cerebrolysin, 1105
a,-Adrenoceptors, 79 Cerebrospinal fluid, 997
a, Agonists, 579 Baclofen, 561 CGP 35348, 561
Alcogene, 417 Balb/c, 433 CGS 9896, 47
Alcohol, 629 Baroreflex, 489 Change in diameter, 891
Alcohol drinking, 949 Basal ganglia, 437 Chicks, 73, 1011
Alcohol intake, 417 Basal magnocellular nucleus, 33 Chickadee, 363
Alcohol preference, 7 Behavior, 701, 795 Chlorambucil, 621
Alcohol withdrawal, 561 Behavioral despair, 891 Chlordiazepoxide, 133
Alcoholism, 949 Behavioral performance, 781 Cholecystokinin, 133
Aldehyde adduct, 949 Behavioral pharmacology, 1049 Cholecystokinin (CCK) receptors, 463
Alfentanil, 523 Behavioral sensitization, 241, 247, 583 Cholesterol, 257
Alkylation, 621 Behavioral thermoregulation, 747 Choline acetyltransferase, 33
Alpha,-adrenergic antagonist, 523 Behavioral toxicity, 503 Cholinergic, 1, 511
Alzheimer’s disease, 769 Behavioural activity types, 263 Cholinergic system development, 1043
Ambulatory activity, 323 Benzodiazepines, 359, 477, 625, 827, 921, Cholinesterase, 235
Aminophylline-induced convulsions, 609 1113 Chronic aminophylline, 609
Amnesia, 849 Benzodiazepine receptors, 253 Chronic phenobarbital, 427
Amnesia models, 859 B-Carboline, 949 Chronic tolerance, 371
Amphetamine, 41, 133, 497, 819 B-Endorphin, 1037 Chronic treatment, 859
Amygdala, 359, 1113 B,-Adrenoceptors, 13 Circadian, 327
Anabolic steroids, 313 B,-Adrenoceptors, 13 Circadian rhythms, 975, 997
Analgesia, 303, 827, 1029 Blood-brain barrier, 341 Circumventricular organ, 489
Anesthesia, 523 Body temperature, 531 Cl” influx, 477
Anesthetic, 1061 BPBA, 561 Classical conditioning, 147, 583, 1061
Animal communication, 835 Bradykinesia, 19 Clenbuterol, 13
Animal model, 549, 683 Brain and plasma concentrations, 287 Clonidine, 79, 579, 849
Anorectic agent, 287 Brain regions, 905 Clozapine, 115, 165, 1025
Antagonists, 295, 573 Bromocriptine, 969 Cocaine, 107, 177, 223, 229, 247, 345, 555,
Anterior hypothalamic-preoptic area, Buprenorphine, 241, 1017 583, 711, 935, 1001, 1007
835 Buspirone, 741 Cocaine withdrawal, 223, 883
Anticholinergic, 363, 813 Butorphanol, 649, 657, 843 Cognition, 683
Ill
IV SUBJECT INDEX
Compensatory response, 1029 Drug dependence, 1049 Forced swim, 729
Condensation product, 949 Drug discrimination, 223, 955 Forced swimming test, 79
Conditioned avoidance responses, 819 Drug interaction, 335 Forgetting functions, 427
Conditioned fear stress, 911 Drug reward, 241 Forskolin, 1093
Conditioned place preference, 241, Drug self-administration, 233 Fourier analysis, 813
1001 Drug tolerance, 1049 Fowls, 295
Context, 763 DSLET, 1109 Free exploration test, 433
Context fear conditioning, 183 DSP-4, 541 Freely moving rat paradigm, 711
Continent tolerance, 1113 DTG, 385 Freezing, 183
Continuous stress, 905 DuP 996, 1067, 1075 Freezing behavior, 911
Convulsions, 561, 1113 Frog, 277
Core temperature, 747 Early protein malnutrition, 393 Frontal cortex, 599
Cortical activation, 235 ECoG, 235 Functional and metabolic tolerance, 371
Cortical slow waves, 235 Ectodermal microceptor preparation, 777
Corticosterone, 287, 729 EEG, 235, 781, 795 GABA, 303, 359, 449
Cortisol, 583 8-Hydroxy-2-(di-n-propylamino)tetralin, 7 GABA agonists, 589
Counting, 943 Electric foot shock stress, 471 GABA antagonists, 589
CPT, 271 Electroconvulsive shock, 849 GABAsg receptor, 561
Cross tolerance, 455, 657 Electrophysiology, 555 GABA-ergic functions, 443
Elevated plus-maze, 133, 171, 801, 985 GABA-transaminase, 801
D, receptors, 73, 165, 197, 205 Elevated T-maze, 549 Gamma-vinyl GABA, 801
D, receptors, 73, 165, 197, 205 Emesis, 385 Gastric emptying, 253
D, receptor antagonist, 19 Endocrine effects, 583 Gastric smooth muscle, 669
DA autoreceptor antagonist, 345 Enriched environment, 393 GBR 12909, 345
DAGO, 737 Environmentally induced oral stereotypies, Generalized anxiety, 219
d-Amphetamine, 345 295 Genetics, 417, 531, 663
DBA/2, 1109 Estradiol, 819 Genetic differences, 975
DBA/2Ibg inbred mice, 257 Ethanol, 371, 413, 417, 789 Genetic model, 165
Defense, 541 Ethanol preference, 949 Glucocorticoid receptor, 961
Defensive behavior, 741 Ethanol withdrawal syndrome, 969 Glucoprivation, 853
Delayed matching to position, 1067 Ethological analysis, 541, 985 Glutamate, 835
Delayed matching to sample, 427 Etorphine, 773 Glutamatergic-cholinergic interactions,
Delayed nonmatching to position, 1067 Excitatory amino acids antagonists, 413 689
6-Opioid receptor, 795, 1109 Excitatory synaptic transmission, 1105 Glycine, 303
6, opioid receptors, 1109 Exploration, 449 Glycine receptor, 707
6, opioid receptors, 1109 Exploratory activity, 801 Gnawing, 737
A’-Tetrahydrocannabinol, 763 Extinction, 935 Growth hormone, 165
Delta opioid receptors, 675 Extrapyramidal motor system, 437 Guinea pig, 133
Dependence, 455 Extrapyramidal side effects, 19
Depression, 165, 353, 759 H-7, 669
Descending pathway, 675 F-344 rats, 1057 Habenula, 555
Desipramine, 13 Factor analysis, 171 Habituation, 449
Development, 353, 997 Fawn-Hooded rat, 759 HAD rats, 417
Dexamethasone, 335 Fear conditioning, 935 Haldol®, 223
Dexamethasone suppression test, 961 Feeding, 25, 85, 143, 377, 737, 843, 853 Hallucinogens, 599
Dexfenfluramine, 287 Feeding pattern, 629 Haloperidol, 197, 205, 223, 309, 813, 969
Dexmedetomidine, 523 Fentanyl, 773, 1017 Handling, 393, 449
Diabetes, 669 Fetus, 795 Harman, 949
Diazepam, 253, 393, 549, 561, 609, 755, Fever, 747 Head-shake response, 107
1113 FG 7142, 133 Head-twitch response, 229
Dietary fat content, 287 50-kHz calls, 835 Heart rates, 489, 629, 747
Dihydro-@-erythriodine, | 5,7-Dihydroxytryptamine, 177 Heritability, 531
Dipeptidyl endopeptidases, 33 5-HT, 359 Hexamethonium, 1
Discrimination learning, 213 5-HT,,, 1083 HI-6, 781
Distress vocalizations, 327, 1011 5-HT,, agonist, 385 High-affinity choline uptake, 689
Dizocilpine, 489, 943, 1049 5-HT, receptors, 107, 129, 165 Hippocampal slices, 1105
DOI, 129, 165, 229 5-HT, receptor antagonist, 19 Hippocampus, 359, 599, 949
DOM, 115 5-HT; antagonists, 67, 385 Histamine, 853
Domestic chicks, 483 5-HT, 449 HL6-7, 781
Domestic fowl, 1011 5-HT release, 1037 Hot plate, 701, 737
Dopamine (DA), 25, 73, 85, 107, 147, 353, Fixed-ratio, 1049 Human, 573, 643, 763
567, 711, 911, 969, 985 Flavored solutions, 417 Hydrocortisone, 335
Dopamine agonist, 901 Flunitrazepam, 47 Hyperalgesia, 701, 1029
Dopamine D, antagonist, 323 Fluoxetine, 121 Hyperphagia, 47
Dopamine receptors, 247, 567 Flupenthixol, 883 Hypnosis, 371
Dopaminergic neuron, 807 Food caching, 363 Hypothermia, 47, 371
Dopaminergic systems, 819 Food carrying, 741 Hypoxia, 129
Dorsal raphe, 555 Food deprivation, 197
DPAT, 93 Food intake, 187, 759, 897 Ibogaine, 711
DPDPE, 675, 795 Food restriction, 295 Ibotenic acid, 33
Drinking, 417 Foot shock stress, 911 Ibuprofen, 335
Drinking behavior, 1 Foraging, 741 ICI118,551, 13
SUBJECT INDEX
ICS 205-930, 67 Medial prefrontal cortex, 911 Nucleus accumbens (NAcc), 85, 155, 711
ICSS, 901 Mefenamic acid, 335 Nucleus tractus solitarius. 489
ICSS paradigm, 345 Melatonin, 327
Immediate-shock deficit, 183 Memory, 363, 549, 707, 849, 1061 Offense, 541
Immobility time, 729 Meperidine, 1017 1-Amino-5-bromouracil (ABU), 471
Immobilization stress, 471 Methadone, 143, 955, 1101 1-Methyl-6-carboline, 949
In vivo electrochemistry (Voltammetry), Methadone dependent, 1101 One trial, 183
711 Methamphetamine sensitization, 323 Open field, 801, 263
In vivo receptor binding, 165 Methlycarbamylcholine, 1 Open-field test, 961
Inbred mice, 271 Methylenedioxyamphetamine, 599 Operant, 25, 143, 843
Inbred strains, 975 Methylhistamine, 853 Operant behavior, 943
Induced seizures, 335 Metoprolol, 13 Operant feeding, 463
Inhibitors, 235 Metyrapone, 729 Operant reinforcement, 377
Initial discriminability, 427 Mice, 13, 263, 323, 433 Opiates, 143, 303, 377, 523, 573, 579, 843
Inositol, 341 Microdialysis, 25, 107 Opioid analgesia, 183, 773
Instrumental behavior, 85 MK-801, 489, 1049 Opioid mixed agonist-antagonist, 241
Interaction, 511 MK-801-induced amnesia, 859 Opioid receptors, 773
Intermediate stage, 921 Monoamine depletion, 79 Opioids, 197, 205, 327, 573, 625, 795, 1011
Intermittent stress, 905 Monoamine metabolism, 471 Organ weights, 905
Intracellular calcium, 1087 Monoaminergic interactions, 541 Organophosphate, 747
Intracerebroventricular, 657, 1093 Monoaminergic receptor, 961 Organophosphate cholinesterase, 503
Intracerebroventricular infusion, 649 Morphine, 649, 657, 737, 773, 1011, 1017, Osmotic minipump, 649, 657, 949
Intracerebroventricular injections, 309 1029, 1037 Ovariectomy, 819
Intrathecal, 303, 1093 Morphine dependence, 1109 Oxazepam, 871
Intrathecal administration, 929 Morris water maze, 1075 Oxytocin, 101
Intravenous, 1029 Morris water task, 257
Ipsapirone, 165, 549 Motivation, 25, 85 p-Chlorophenylalanine (PCPA), 483
Ischemia, 129 Motor activity, 747 P Rats, 417
Isolation, 13 Motor control, 25 Paeoniflorin, 213
Isolation distress, 327 Motor reflex, 827 Pain, 303, 701, 1011
Isolation stress, 1011 Mouse, 133, 689, 701, 871, 1043 Pain control system (descending),
IV surgery, 233 Movement initiation, 777 tolerance, 1037
p-opioid receptors, 1109 Palatability, 417
Jugular catheterization, 233 Muscarinic receptors, 405 Paradoxical sleep, 921
Muscle rigidity, 523 Paragigantocellularis, 121
Kainic acid, 33 Muscle tone, 523 Parkinson-like, 813
Kappa receptor subtypes, 929 Myoclonus, 129 Parkinson’s disease, 147
Ketamine, 1061 Parkinsonism, 437
Ketanserin, 129, 849 Naloxone, 183, 377, 573, 1011 Paroxetine, 281
Kindling, 1113 Naloxone benzoylhydrazone, 929 Parus atricapillus, 363
Naloxone withdrawal, 1109 Passive avoidance, 33, 849
LAD, 417 Naltrexone, 197, 205, 589 Passive avoidance task, 807
Latency, 891 Naltrindole, 795 Passive avoidance test, 859
Layer 5, 639 NAN-190, 385 Pavlovian facilitator, 955
Learning, 147, 1061, 1083 Narcotics, 827 PD135158, 433
Learning and memory, 807 NECA, 271 Pentobarbital, 589
Lesion, 511 Neonate, 1017 Peptides, 1105
LH, 789 Neophobia, 433 Percentile schedules, 943
Li-pilocarpine seizures, 341 Nerve agent, 503 Performance, 497, 827
Licking, 813 Nerve growth factor, 701, 1043 Perioral movements, 437
Light/dark choice test, 433 Neurobehavioral ontogeny, 1043 Pertussis toxin, 773
Limbic system, 949 Neurochemistry, 1075 PGO waves, 93
Linopirdine, 1067, 1075 Neuroleptics, 19, 813 Phaclofen, 561
Lithium, 341, 975, 1087 Neuromodulation, 443 Pharmacodynamics, 335
Lobeline, 877 Neurotoxicity, 335 Phencyclidine, 1025
Locomotion in open field, 47 Nicotine, 1, 511, 531, 755, 769, 807, 877 Photo-phobic test, 541
Locomotor activity, 41, 67, 101, 241, 271, Nicotine reinforcement, 67 Physical activities, 629
531, 711, 1043 Nictitating membrane response, 1061 Physostigmine, 363, 1067
Locus coeruleus, 541 Nitrous oxide, 573 Picrotoxin, 589
Long-term potentiation, 707 NMDA receptor, 707 Pigeons, 385, 955
Long-term treatment, 263 N-Methylcarbamylcholine phosphoinosi- Pigs, 463
LSD, 115 tide, 405 Piracetam, 683
Lurcher mutants, 777 N-Methyl-D-aspartate, 489 Place approach, 1001
N-methyl-D-aspartate receptor, 859 Plasma corticosterone, 905
Male sexual behavior, 303 Nociception, 303, 737827 Platelets, 1087
Marijuana, 187, 643, 763 Nootropics, 263 Plus-maze test, 47
Maternal deprivation, 961 Nor-binaltorphimine, 929 Polydipsia, 1
Maternal induction behavior, 871 Noradrenaline, 13, 303, 541 Postintoxication incapacitation, 781
Maximal electroshock, 609 Noradrenaline turnover, 905 Posttreatment, 323
mCPP, 93, 165, 759 Noradrenergic, 511 Potency, 643
MDL 72222, 67 Norepinephrine, 57 PRE-084, 859
Mecamylamine, 1, 859, 877 NSAID, 335 Preference, 417
VI SUBJECT INDEX
Pregnancy, 795 Security of implantation, 639 Supraspinal, 1037
Pregnant, 1101 Sedation, 101 Supraspinal analgesia, 773
Prenatal pup treatment, 871 Seizure, 1113 Surgical method, 233
Proactive interference, 427 Selective breeding, 531 Surgical procedure, 639
Prolactin, 583, 789 Self-administration, 177, 643, 763 Swim test, 41
Prolyl endopeptidase, 33 Self-stimulation, 901 Swimming activity, 79
Propranolol, 13 Senescence-accelerated mice (SAM), 769 Synaptosomes, 1093
Protective drugs, 503 Sensitization, 883, 935
Protein kinase C, 669 Sensorimotor gating, 155, 877 Tabun, 781
Psychological stress, 911 Sensory-discriminative, 827 Tacrine, 213
Psychomotor, 573 Septo-hippocampal pathway, 689 Tail flick, 737
Psychostimulant behavior, 711 Septum, 689 Tail pinch, 737
Pulsatile secretion, 789 Serotonergic drugs, 313 Tardive dyskinesia, 309, 663
Purkinje cells, 443 Serotonin, 57, 93, 107, 121, 129, 177, 303, Tele-methylhistamine, 997
Pygmy goats, 897 483, 599, 759, 849, 911, 1083 Telemetry, 747
Pyridostigmine, 503 Serotonin (5-HT), 555, 711, 741 Testosterone propionate, 313
Serotonin receptors, 115 THC, 643
Quail, 625
Serotonin-1A receptors, 7 Theophylline, 335
Quinpirole, 73, 155, 197, 205, 985
Sexual behavior, 121 Thermal nociception, 1011
Sexual exhaustion, 121 Thermogenesis, 1057
Rabbit, 599, 1061 Short-term memory, 683 Thermoregulation, 1011
Radioligand binding, 271, 625 o sites, 859 Threshold, 827
Rapid eye movement (REM) sleep, 93, 413 Simple phobia, 219 Thrombin, 1087
Rats, 41, 115, 133, 171, 223, 281, 309, 393, Single-unit recording, 555 Time course study, 165
417, 497, 541, 555, 589, 663, 729, 741, SKF-38393, 73, 197, 205, 985 Tobacco, 769
807, 813, 835, 849, 883, 921, 969, 1001, Sleep, 93, 921 Tolerance, 287, 455, 477, 609, 649, 883,
1007, 1049, 1067, 1075, 1083, 1087, Sleep-like states, 277 1029, 1037
1101, 1105, 1113 Slow-wave sleep, 413 Tolerance dissipation, 1113
Rate of forgetting, 427 SM-9018, 19 Tongue, 813
Rearing behavior, 711 Social interaction model, 281 Tonic immobility, 625
Receptors, 1083 Soda, 629 Tonic nociception, 1017
Receptor plasticity, 247 Soman, 503, 781 Trait anxiety, 433
Receptor subtypes, 295 Spatial learning, 707 Transfected M, gene, 405
Rectal temperature, 165 Spatial navigation/memory, 1075 Treadmill running, 1057
Regression residuals, 531 Spatial reference memory, 689 Tremor, 561
Reinforcement, 25, 763, 843 Spinal analgesia, 773 Triazolam, 455
Reinforcement density, 943 Spinal cord, 303, 1037 Tryptophan hydroxylase, 277
Reinforcement loss, 943 Spinal GABA, 675 22-kHz calls, 835
Reinforcing effects, 643 Spinocerebellar ataxia, 443 2-Deoxy-D-glucose, 205, 853
REM sleep deprivation, 79 Startle, 155, 1025
Reserpine, 73, 229 State anxiety, 433 (+ )-UH232, 345
Respiration, 1011 Steady state, 287 U-50,488, 657
Response rate, 943 Stearate microelectrode, 711 U50,488H, 929
Retention, 1061 Stereotypy, 711 Ultrasonic vocalization, 835
Rhesus macaque, 503 Steroids, 335
Risk assessment, 985 Stimulus control, 115 Vacuous chewing movements, 309
RJM, 663 Strains, 57 Vasopressin, 897
RMI-81582, 165 Stress, 57, 353, 449, 737 Vigabatrin, 801
Ro15-1788, 47 Stress intensity, 911 Vigilance, 497
Rotarod performance, 443 Stress-rest cyclicity, 905 Vocalizations, 827
Rotation, 147 Striatum, 147 Volunteer, 573
Run length, 943 Subcutaneous, 1029
Running-wheel, 263 Subcutaneous administration, 1007 Water maze, 511
Subjective, 573 Withdrawal, 41, 253
Satiety, 187 Subjective effects, 643, 763
SCH-23390, 197, 205, 807, 985 Subsensitive, 165 Y-maze test, 859
SCH 39166, 567 Substantia nigra, 147, 737 YM-09151-2, 323
Schedule-controlled behavior, 589, 1049 Subtypes, 133
Schizophrenia, 155, 877 Suckling, 1043 Zinc, 477
Scopolamine, 133, 363, 807, 813, 1043, 1067 Sulpiride, 807, 985 Zolpidem, 47, 455
PHARMACOLOGY BIOCHEMISTRY
& BEHAVIOR
VOLUME 49 1994
AUTHOR INDEX
Abood, L. G., 405 Botez, M. I., 777 Durazzo, T. C., 1001, 1007 Grigoryan, G. A., 511
Adegboyega, P. A., 1087 Boyson, S. J., 147 Durieux, C., 133 Grilly, D. M., 497
Adell, A., 949 Brioni, J. D., 755 Dussaubat, N., 819 Grisel, J. E., 1029
Afargan, M., 335 Briscoe, R. J., 1001, 1007 Duttaroy, A., 733 Guan, X.-M., 7
Agam, G., 341 Broderick, P. A., 711 Duvauchelle, C. L., 233 Giimiisel, B., 891
Agrawal, A. K., 443 Brown, G. C., 503 Guo, X. Y., 583
Ahlenius, S., 101 Brudzynski, S. M., 835 El-Hwuegi, A., 801
Airaksinen, E. M., 997 Buccafusco, J. J., 1 El-Zahaby, H. M., 1061 Hafen, T., 975
Akarsu, E. S., 969 Buchanan, C. P., 483 Ellinwood, E. H., Jr., 883 Halgren, E., 235
Alleva, E., 701, 871 Bueno, L., 253 Elsohly, M. A., 187 Harper, D. N., 427
Almeida, S. S., 393 Burke, K. A., 643 Eng, F., 711 Harro, J., 801
Aloe, L., 701 Buxton, A., 1067 Engelman, K., 187 Hartgraves, S. L., 503
Alonso, S. J., 353 Esquifino, A. I., 789 Hartle, D. K., 489
Alster, P., 101 Calamandrei, G., 1043 Essman, W. D., 107 Harvey, J. A., 599
Andreassen, O. A., 309 Callan, O. A., 1067 Hasan, M., 443
Andrews, N., 359 Carriero, D. L., 25 Fahey, K. A., 827 Hasegawa, T., 807
Anisman, H., 57 Carro, E., 789 Feng, Y. Z., 649, 657 Hashemi, T., 567
Arai, H., 769 Chait, L. D., 643 Fernandes, C., 359 Hawkins, M. F., 737
Arce, A., 789 Chan, A. W. K., 371 File, S. E., 219, 359, 449, 625 Henderson, N. D., 531
Asakura, W., 79 Chen, P., 1061 Finkelstein, J. E., 707 Hendricks, S. E., 121
Aulakh, C. S., 615, 759 Chen, S.-W., 47 Fiorella, D., 313 Hengemihle, J. M., 707
Ayres, J. J. B., 183 Cheng, P. Y., 795 Fischman, M. W., 763 Henningfield, J. E., 583
Chernet, E., 7 Fitten, L. J., 235 Henriksen, S. J., 413
Backon, J., 335 Chiu, T. H., 477 Florio, C., 271 Herning, R. I., 583
Baez, M., 729 Cleary, J., 143 Fluck, E., 449 Hill, J. L., 615, 759
Baeza, R., 819 Coalson, D. W., 573 Foltin, R. W., 763 Hill, W. L., 483
Baker, G. B., 177 Coen, K. M., 67 Fong, C.-S., 147 Hillegaart, V., 101
Ball, W. A., 93 Cohen, C., 455 Fontana, D. J., 1067, 1075 Ho, I. K., 649, 657
Barber, D. A., 579 Cole, J. C., 985 Fowler, S. C., 813 Hobbs, D. J., 197
Bardo, M. T., 241 Corrigall, W. A., 67 Frei, F., 171 Hodges, H., 511
Baskin, P. P., 437 Cousins, M. S., 25, 85 Friedhoff, A. J., 663 Hoffer, B. J., 147
Baskys, A., 1105 Criado, J. R., 413 Fu, X.-W., 835 Hoffman, A., 335
Bass, P. P., 1093 Cruz, A. P. M., 171 Fujimoto, J. M., 675 Hogg, S., 219, 625
Baumeister, A. A., 737 Cunningham, K. A., 555 Fuller, R. D., 737 Holloway, F. A., 223, 1001,
Bednarczyk, J. M., 523 Curzon, P., 877 1007
Belmaker, R. H., 341 Czuczwar, S. J., 609 Galbicka, G., 943 Holmes, B. B., 675
Belzung, C., 433 Gandolfo, G., 921 Homma, I., 669
Benavente, F., 819 Darmani, N. A., 229 Gauvin, D. V., 223, 1001, 1007 Hong, E., 1083
Beninger, R. J., 363 Das, S., 813 Gendron, T. M., 583 Hope, H., 1101
Berkowitz, R. J., 25 Daud, M. M., 393 Genkova-Papazova, M., 849 Hoskins, B., 649, 657
Bersudsky, Y., 341 Davies, M. F., 47 Gewiss, M. V., 589 Hubert, I., 683
Beuzen, A., 433 Davis, T., 733 Geyer, M. A., 155 Hudson, J. L., 147
Bevins, R. A., 183 De Acetis, L., 701 Ghoneim, M. M., 1061 Hughes, R. A., 1011
Beyer, C., 303 De Castro, J. M., 629 Gianutsos, G., 437 Humeniuk, R. E., 561
Billington, C. J., 143, 377, 843 De Oliveira, L. M., 393 Gibson, T. R., 241 Husain, R., 443
Blackburn, T. P., 281 Decker, M. W., 877 Gilhar, D., 335 Hussong, M. J., 129
Blatt, E. J., 1067 DeFries, J. C., 531 Goldberg, S. R., 41, 589
Blick, D. W., 503 Della Seta, D., 701 Goémora, P., 303 Ido, H., 165
Block, R. I., 1061 Derrien, M., 133 Gondoh, Y., 905 Ikasaki, Y., 769
Boag, P. T., 363 Dewey, W. L., 1017 Gonzalez-Mariscal, G., 303 Ikeda, K., 19
Bodnar, R. J., 197, 205 Diaz-Véliz, G., 819 Gordon, C. J., 747 Ikemoto, S., 327
Bonnafous, C., 253 Dib, B., 639 Gorelick, D. A., 583 Il’ina, A. D., 1109
Bonson, K. R., 313 Doi, C., 769 Gottesmann, C., 921 Imaizumi, M., 471
Bontemps, R., 777 Dose, J. M., 73 Goulden, K. L., 223, 1001, Inazu, M., 669
Borisenko, S. A., 33 Dringenberg, H. C., 741 1007 Ingram, D. K., 707
Borland, J. L., 1011 Du, W., 599 Graeff, F. G., 171, 549 Inoue, T., 911
Borowski, T. B., 935 Ducos, B., 133 Gray, J. A., 511 Inouye, G. T., 1075
Borszcz, G. S., 827 Duffy, R. A., 567 Griffiths, J., 57 Ishibashi, T., 19
Vill AUTHOR INDEX
Ishida, K., 19 Machida, H., 471 Palumbo, P. A., 115 Shamoto, A., 669
Itoh, A., 807 Maguire, P. A., 47 Panksepp, J., 327 Shanks, N., 57
Maier, S. F., 1029 Paris, J. M., 555 Shapiro, Y., 341
Jaffard, R., 689 Maisky, A. I., 1109 Parish, D. W., 859 Sharma, V., 405
Jagers, T., 943 Mann, G. L., 93 Parker, B. K., 955 Shaw, L. M., 187
Jahkel, M., 263 Mannist6, P. T., 33 Parrott, R. F., 463 Sherif, F., 801
Jarvikyla, M., 853 Marco, J., 789 Paterson, S., 625 Sheu, S.-S., 405
Jaw, S. P., 129, 649 Marighetto, A., 689 Pauly, J.R., 1 Shiba, K., 165
Johnson, C. P., 827 Marks, M. J., 531 Perryman, K. M., 235 Shimizu, M., 213
Johnson, R. G., 313 Marley, R. J., 589 Persico, A. M., 41 Shimizu, T., 905
Johnson, R. M., 1075 Marmarosh, N., 405 Pert, A., 399 Shrier, E. M., 483
Jorgensen, H. A., 309 Maruyama, Y., 769 Petkov, V. D., 849 Simon, B. B., 497
Jou, M.-J., 405 Matsuguchi, N., 905 Petri, H. L., 707 Sinden, J. D., 511
Joyner, C., 883 Matsumoto, K., 13, 79, 213 Petruzzi, S., 871 Singh, A., 107
Jung, J.-S., 1037 Matsumoto, R. R., 129 Phelan, F. T., 711 Smolen, A., 531
Mattes, R. D., 187 Philippens, I. H. C. H. M., Song, D.-K., 1037
Kalynchuk, L. E., 1113 Maurice, T., 859 781 Soong, Y., 795
Karmanova, I. G., 277 Mayr, M. T., 763 Pickworth, W. B., 583 Su, T.-P., 859
Katono, Y., 807 McBride, W. J., 7 Pierce, T. L., i101 Sufka, K. J., 1011
Kautz, M. A., 943 McCallum, M. D., 737 Pineau, N., 433 Suh, H.-W., 1037
Kayaalp, S. O., 891 McCormick, T. M., 1011 Pinel, J. P. J., 1113 Sumiyoshi, T., 165
Kayaalp, S. O., 969 McCort-Tranchepain, I., 133 Pinto, E., 335 Sunal, R., 891
Kelly, T. H., 763 McCullough, L. D., 25 Popova, N. K., 277 Suzuki, K., 165
Kennett, G. A., 281 McIntyre, C. P., 1113 Porsolt, R. D., 683 Svensson, K., 345
Kido, H., 165 McLaughlin, C. R., 1017 Prendergast, M. A., 121 Swerdlow, N. R., 155
Kim, D. J. B., 877 McQuade, R. D., 567 Privat, A., 859 Szeto, H. H., 795
Kim, Y.-H., 1037 Meguro, K., 769 Prospero-Garcia, O., 413
King, G. R., 883 Melchers, B. P. C., 781 Pugh, G., Jr., 1093 Tackett, R. L., 579
Kippin, T. E., 1113 Meneses, A., 1083 Takahashi, K., 961
Kiviranta, T., 997 Micheau, J., 689 Rabin, R. A., 313 Tanaka, M., 905
Kiyatkin, E. A., 247 Mikuni, M., 961 Rady, J. J., 675 Taylor, L. A., 567
Kleinrok, Z., 609 Milinkevich, D., 683 Rankin, J., 871 Thapar, P., 573
Kling-Petersen, T., 345 Miller, M., 955 Reynolds, F. A., 233 Thompson, T., 143
Klodt, P. M., 1109 Miller, S., 257 Roberts, D. C. S., 177 Thomson, L. E., III, 583
Knapp, C. M., 901 Mills, A., 625 Rodgers, R. J., 985 Thorndike, E. B., 589
Koch, J. E., 197, 205 Mineau, P., 363 Rodriguez, M., 353 Tian, B., 489
Koeppl, B., 583 Misslin, R., 433 Rolinski, Z., 609 Tice, M. A. B., 567
Kofman, O., 341 Mitchell, S. N., 511 Romaniuk, A., 541 Tolliver, T., 615
Kokkinidis, L., 935 Miyazaki, S., 471 Romano, A. G., 599 Tomaz, C., 549
Kornelsen, R. A., 741 Mizoguchi, K., 905 Roques, B. P., 133 Traversa, U., 271
Kornetsky, C., 233, 901 Mora, S., 819 Rosati, A. M., 271 Truong, D. D., 129
Kostal, L., 295 Mori, H., 165 Rosenberg, H. C., 477 Tsai, N. F., 47
Koyama, T., 911 Mori, K. J., 961 Rosengarten, H., 663 Tseng, Y. T., 649, 657
Kozlachkova, E. Y., 277 Morrison, A. R., 93 Ross, R. J., 93 Tsuchiya, K., 911
Kulikov, A. V., 277 Muneoka, K., 961 Rossi, R., 897 Tsuda, A., 905
Kundu, G. C., 621 Murphy, D. L., 615, 759 Rothman, R. B., 399, 583 Tuimisto, L., 853
Kuribara, H., 323 Murphy, M. R., 503 Roux, S., 683 Tulloch, I. F., 281
Kuroda, Y., 961 Myers, R. D., 417, 949 Rowland, N. E., 287 Timer, M., 1057
Kutepova, O., 33 Rowlett, J. K., 241 Tuomainen, P., 33
Nabeshima, T., 807, 859 Rudski, J. M., 143, 377, 843 Tuomisto, L., 997
Lafuente, A., 789 Nakamura, M., 19, 121
Lalonde, R., 777 Nakamura, T., 769 Sakai, Y., 669 Uhl, D. R., 41
Lankford, M. F., 417 Narita, M., 657 Sakamoto, H., 165 Urasaki, K., 165
Laviola, G., 871 Navarro, E., 353 Salamone, J. D., 25, 85, 437 Uvns-Moberg, K., 101
Lazarova-Bakarova, M.., Nelson, E., 327 Sanford, L. D., 93 Uzbay, I. T., 969
849 Nikulina, E. M., 985 Sanger, D. J., 455
Leander, J. D., 385 Nitta, A., 807 Santucci, L. B., 393 Valanzano, A., 1043
Lecklin, A., 853 Sasaki, H., 769 Vanderwolf, C. H., 741
Lenégre, A., 683 Oehler, J., 263 Savory, C. J., 295 Vertua, R., 271
Levine, A. S., 143, 377, 843 Ogawa, T., 961 Scarpace, P. J., 1057 Viana, M. B., 549
Li, M., 477 Ohno, Y., 19 Schaal, D. W., 143, 955 Vickers, G., 177
Li, T.-K., 7 Ohta, H., 13, 79, 213 Schaefer, L. A., 205 Volosin, M., 729
Lichtor, J. L., 573 Ojima, K., 13 Scharrer, E., 897 Voronina, T., 33
Lightowler, S., 281 Okada, K., 19 Scherschlicht, R., 921 Voronova, I. P., 277
Ljung, E., 345 Okorodudu, A. O., 1087 Schindler, C. W., 41, 589
Loew, G. H., 47 Onaivi, E. S., 47 Schullek, J. R., 621 Wan, F. J., 155
Loh, E. A., 177 O’Neill, A. B., 755 Schumacher, H.-E., 263 Wang, D. X., 405
Lépez, M., 789 O’Neill, J., 235 Schweitzer, J. W., 663 Watanabe, H., 13, 79,
Loron, P., 777 Ong, J., 561 Seggos, A. E., 93 213
Lucki, I., 107 Oreland, L., 801 Seth, P. K., 443 Watkins, L. R., 1029
Lumeng, L., 7 Orozco, S., 629 Shah, S., 733 Watson, J. E., 427
AUTHOR INDEX
Wechsler, R. T., 711 Williamson, I. J. R., 281 Wu, D.-L., 795 Yokoo, H., 905
Wehner, J. M., 257 Wilson, I. B., 621 FOUR F Revy SE
Weinger, M. B., 523 Winter, J. C., 115, 313 Yajnik, S., 573 Yukhananovy, R. Y., 1109
Welch, S. P., 929, 1093 Wlaz, P., 609 Yamada, M., 769
Wessinger, W. D., 1049 Wojtowicz, J. M., 1105 Yamaguchi, N., 165 Zacny, J. P., 573
White, J. M., 561 Wolff, M. C., 385 Yamaguchi, S., 769 Zagrodzka, J., 541
White, K. G., 427 Wollnik, F., 975 Yang, X., 1 Zaitsev, S. V., 1109
Wieczorek, M., 541 Wolthuis, O. L., 781 Yells, D. P., 121 Zhu, B., 669
Wiertelak, E. P., 1029 Wong, E. H. F., 1067 Yenice, S., 1057 Zolman, J. F., 73
Wiley, J. L., 1025 Wozniak, K. M., 615 Yoburn, B. C., 733 Zolotov, N., 33